Bictegravir vs Raltegravir

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV integrase · full HIV pipeline

Bictegravir · Biktarvy

Marketed by Gilead Sciences

Approved in HIVsmall molecule
Reliable signal

NCT02607956 · Phase 3 · completed

This was a randomized, double-blind, active-controlled Phase 3 trial in 657 treatment-naive HIV-1 adults, powered for non-inferiority with a 12% margin. The primary endpoint was the FDA snapshot proportion with HIV-1 RNA <50 copies/mL at Week 48, a clinical virologic endpoint. The pre-specified non-inferiority comparison was met: B/F/TAF 89.4% vs DTG+F/TAF 92.9%, difference -3.5 (95.002% CI -7.9 to 1.0), with the confidence interval entirely within the 12% margin; the superiority test was not significant.

Next expected readout: December 2026 · NCT06830668 (registry estimate)

Reported efficacy

Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm: Participants with HIV-1 RNA ≥50 copies/mL at week 48 (FDA snapshot): 0.4% with B/F/TAF vs 1.1% with dolutegravir plus emtricitabine/tenofovir alafenamide; difference -0.7% (95% CI -2.8% to 1.0%), inside the pre-specified 4% non-inferiority margin (CT.gov posted analysis). (met)

Result source: NCT03110380

Raltegravir · Isentress

Marketed by Merck & Co.

Approved in HIVsmall molecule
Reliable signal

NCT00293254 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial with 351 patients, using HIV-1 RNA suppression - a regulator-accepted, disease-defining measure - as the primary endpoint. The raltegravir arm showed clearly higher suppression rates than placebo at both Week 16 and Week 48, with confidence intervals that do not overlap, indicating a statistically robust and clinically meaningful benefit.

Next expected readout: January 2028 · NCT02140255 (registry estimate)

Reported efficacy

Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks); Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 48 (48 Weeks); Double-Blind Extension - Week 156: Percentage of Participants Achieving HIV RNA <400 Copies/mL (156 Weeks); Open-Label Extension - Week 240: Percentage of Participants Achieving HIV RNA <400 Copies/mL (240 Weeks): Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks): Raltegravir 400 mg b.i.d. + OBT 77.3% (95% CI 71.3 to 82.6) vs Placebo + OBT 42.9% (95% CI 33.8 to 52.3) (met)

Result source: NCT00293254

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBictegravirRaltegravir
HIV-1 RNA below 50 copies/mL (week 48)92.4% vs 93%vs ABC/DTG/3TCwk 48 · n 314NCT02607930
5 other results
  • 81.5% vs 84.1% wk 144 · n 314 · Phase 3 · secondary NCT02607930
  • 87.9% vs 89.8% wk 96 · n 314 · Phase 3 · secondary NCT02607930
  • 93.3% vs 91.1% wk 48 · n 284 · Phase 3 · secondary NCT03110380
  • 96.9% vs 93.9% wk 24 · n 65 · Phase 2 · primary NCT02397694
  • 96.9% vs 90.9% wk 48 · n 65 · Phase 2 · secondary NCT02397694
—Not posted · NCT01195467
HIV-1 RNA 50 copies/mL or more (week 48)0.4% vs 1.1%vs DTG + F/TAFwk 48 · n 284NCT03110380—Not posted · NCT01195467
CD4 count, change (week 48)180 vs 201vs DTG + F/TAFwk 48 · n 290NCT02607956
6 other results
  • 235 vs 228 wk 48 · n 294 · Phase 3 · secondary NCT02607930
  • 18 vs 36 wk 48 · n 262 · Phase 3 · secondary NCT03110380
  • 237 vs 281 wk 96 · n 269 · Phase 3 · secondary NCT02607956
  • 287 vs 288 wk 96 · n 276 · Phase 3 · secondary NCT02607930
  • 278 vs 289 wk 144 · n 262 · Phase 3 · secondary NCT02607956
  • 299 vs 317 wk 144 · n 255 · Phase 3 · secondary NCT02607930
98.4 vs 39.8+58.6 vs placebo400 mg b.i.d. · wk 48 · n 217NCT00293254
6 other results
  • 120.2 vs 49.4 400 mg b.i.d · wk 48 · n 230 · Phase 3 · secondary NCT00293267
  • 157.2 vs 54.2 400 mg b.i.d. · wk 156 · n 189 · Phase 3 · secondary NCT00293254
  • 170.9 vs 71.0 400 mg b.i.d · wk 156 · n 207 · Phase 3 · secondary NCT00293267
  • 8.6 vs 21.9 wk 24 · n 19 · Phase 4 · primary NCT00772590
  • 2.7 vs 21.9 wk 24 · n 19 · Phase 4 · primary NCT00772590
  • 192 vs 205 wk 48 · n 9 · Phase 4 · primary NCT00762892

HIV-1 RNA below 50 copies/mL (week 48)

Bictegravir
92.4% vs 93%vs ABC/DTG/3TCwk 48 · n 314NCT02607930
5 other results
  • 81.5% vs 84.1% wk 144 · n 314 · Phase 3 · secondary NCT02607930
  • 87.9% vs 89.8% wk 96 · n 314 · Phase 3 · secondary NCT02607930
  • 93.3% vs 91.1% wk 48 · n 284 · Phase 3 · secondary NCT03110380
  • 96.9% vs 93.9% wk 24 · n 65 · Phase 2 · primary NCT02397694
  • 96.9% vs 90.9% wk 48 · n 65 · Phase 2 · secondary NCT02397694
Raltegravir
—Not posted · NCT01195467

HIV-1 RNA 50 copies/mL or more (week 48)

Bictegravir
0.4% vs 1.1%vs DTG + F/TAFwk 48 · n 284NCT03110380
Raltegravir
—Not posted · NCT01195467

CD4 count, change (week 48)

Bictegravir
180 vs 201vs DTG + F/TAFwk 48 · n 290NCT02607956
6 other results
  • 235 vs 228 wk 48 · n 294 · Phase 3 · secondary NCT02607930
  • 18 vs 36 wk 48 · n 262 · Phase 3 · secondary NCT03110380
  • 237 vs 281 wk 96 · n 269 · Phase 3 · secondary NCT02607956
  • 287 vs 288 wk 96 · n 276 · Phase 3 · secondary NCT02607930
  • 278 vs 289 wk 144 · n 262 · Phase 3 · secondary NCT02607956
  • 299 vs 317 wk 144 · n 255 · Phase 3 · secondary NCT02607930
Raltegravir
98.4 vs 39.8+58.6 vs placebo400 mg b.i.d. · wk 48 · n 217NCT00293254
6 other results
  • 120.2 vs 49.4 400 mg b.i.d · wk 48 · n 230 · Phase 3 · secondary NCT00293267
  • 157.2 vs 54.2 400 mg b.i.d. · wk 156 · n 189 · Phase 3 · secondary NCT00293254
  • 170.9 vs 71.0 400 mg b.i.d · wk 156 · n 207 · Phase 3 · secondary NCT00293267
  • 8.6 vs 21.9 wk 24 · n 19 · Phase 4 · primary NCT00772590
  • 2.7 vs 21.9 wk 24 · n 19 · Phase 4 · primary NCT00772590
  • 192 vs 205 wk 48 · n 9 · Phase 4 · primary NCT00762892
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety

Coverage. Bictegravir: 7 of 7 rows · Raltegravir: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBictegravir
Rows use multiple source trials
Raltegravir
Rows use multiple source trials
CD4
absolute change · count
Maintenance
258 vs 188 DTG + F/TAF count @ 48wka,b,c
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
189.1 vs 163.3 Efavirenz count @ 48wk400 mg b.i.d.a,b,c
NCT00369941 · Phase 3
CD4+
absolute change · cells/uL
No placebo or comparator arm
382.4211 cells/uL @ 48wkd,b,c
NCT04530630 · Phase 4 · registry result, not featured evidence
232 cells/uL @ 48wkd,b,c
NCT02131233 · Phase 3 · registry result, not featured evidence
HIV RNA Less Than 50 Copies
responder rate · % of participants
Maintenance
89.4% (n=320) vs 92.9% (n=325) DTG + F/TAF @ 48wkb,c
NCT02607956 · Phase 3 · HIV · phase 3
59.6% (n=228) vs 34.5% (n=119) placebo @ 48wk400 mg b.i.d.b,c
NCT00293254 · Phase 3 · combination
1 other source trial
64.5% (n=231) vs 31.4% (n=118) placebo @ 48wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
Dropout rate
18.7%e
NCT02607956 · Phase 3 · HIV · phase 3
show 15 more results
17.1%B/F/TAF
NCT02607930 · Phase 3 · HIV · phase 3
—B/F/TAF to B/F/TAF
NCT02607930 · Phase 3 · HIV · phase 3
7.4%B/F/TAF
NCT03110380 · Phase 3
—Double-Blind Treatment Phase B/F/T
NCT03110380 · Phase 3
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · combination
5%
NCT04530630 · Phase 4 · registry result, not featured evidence
11.9%
NCT05405751 · Phase 4 · registry result, not featured evidence
—
NCT03656783 · Phase 3 · registry result, not featured evidence
4.6%BIC + F/TAF
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
—BIC + F/TAF (Double-Blind Randomiz
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
20%50 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
20%100 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
20%5 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
23.7%400 mg b.i.d.f
NCT00293254 · Phase 3 · combination
show 27 more results
—400 mg b.i.d.
NCT00293254 · Phase 3 · combination
—400 mg b.i.d
NCT00293267 · Phase 3 · combination
17.5%400 mg b.i.d
NCT00293267 · Phase 3 · combination
25.5%400 mg b.i.d.
NCT00369941 · Phase 3
15.4%
NCT01147107 · Phase 4 · registry result, not featured evidence
9.5%
NCT03374358 · Phase 4 · registry result, not featured evidence
0%
NCT03667547 · Phase 4 · registry result, not featured evidence
—Arm A Raltegravir
NCT03205566 · Phase 4 · registry result, not featured evidence
—Arm B Raltegravir Lamivudine
NCT03205566 · Phase 4 · registry result, not featured evidence · combination
10.5%
NCT02383355 · Phase 4 · registry result, not featured evidence
38.5%
NCT00939874 · Phase 4 · registry result, not featured evidence
0%
NCT00843713 · Phase 4 · registry result, not featured evidence
22.2%
NCT01332227 · Phase 4 · registry result, not featured evidence · combination
27.3%
NCT00870363 · Phase 4 · registry result, not featured evidence · combination
6.7%Switch to Tenofovir/Emtricitabine
NCT01270802 · Phase 4 · registry result, not featured evidence · combination
—Switch to Tenofovir/Emtricitabine/
NCT01270802 · Phase 4 · registry result, not featured evidence
35.7%
NCT00762892 · Phase 4 · registry result, not featured evidence
0%
NCT01335620 · Phase 4 · registry result, not featured evidence · combination
6.7%Intervention Arm No.1
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
28.6%Intervention Arm No.2
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
0%Hyper-immune Bovine Colostrum
NCT00772590 · Phase 4 · registry result, not featured evidence
0%Raltegravir + Hyper-immune Bovine
NCT00772590 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00631449 · Phase 4 · registry result, not featured evidence
7.5%1200 mg QD
NCT03029689 · Phase 3 · registry result, not featured evidence · combination
4.1%
NCT02284035 · Phase 3 · registry result, not featured evidence · combination
—1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
12.4%Reformulated Raltegravir
NCT02131233 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
1.2%e
NCT02607956 · Phase 3 · HIV · phase 3
show 15 more results
0%B/F/TAF
NCT02607930 · Phase 3 · HIV · phase 3
—B/F/TAF to B/F/TAF
NCT02607930 · Phase 3 · HIV · phase 3
1.1%B/F/TAF
NCT03110380 · Phase 3
—Double-Blind Treatment Phase B/F/T
NCT03110380 · Phase 3
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · combination
—
NCT04530630 · Phase 4 · registry result, not featured evidence
—
NCT05405751 · Phase 4 · registry result, not featured evidence
—
NCT03656783 · Phase 3 · registry result, not featured evidence
1.5%BIC + F/TAF
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
—BIC + F/TAF (Double-Blind Randomiz
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
—50 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
—100 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
—25 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
—5 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
0.9%400 mg b.i.d.f
NCT00293254 · Phase 3 · combination
show 27 more results
—400 mg b.i.d.
NCT00293254 · Phase 3 · combination
—400 mg b.i.d
NCT00293267 · Phase 3 · combination
0.4%400 mg b.i.d
NCT00293267 · Phase 3 · combination
5%400 mg b.i.d.
NCT00369941 · Phase 3
—
NCT01147107 · Phase 4 · registry result, not featured evidence
—
NCT03374358 · Phase 4 · registry result, not featured evidence
—
NCT03667547 · Phase 4 · registry result, not featured evidence
—Arm A Raltegravir
NCT03205566 · Phase 4 · registry result, not featured evidence
—Arm B Raltegravir Lamivudine
NCT03205566 · Phase 4 · registry result, not featured evidence · combination
10.5%
NCT02383355 · Phase 4 · registry result, not featured evidence
—
NCT00939874 · Phase 4 · registry result, not featured evidence
—
NCT00843713 · Phase 4 · registry result, not featured evidence
5.6%
NCT01332227 · Phase 4 · registry result, not featured evidence · combination
—
NCT00870363 · Phase 4 · registry result, not featured evidence · combination
0%Switch to Tenofovir/Emtricitabine
NCT01270802 · Phase 4 · registry result, not featured evidence · combination
—Switch to Tenofovir/Emtricitabine/
NCT01270802 · Phase 4 · registry result, not featured evidence
—
NCT00762892 · Phase 4 · registry result, not featured evidence
—
NCT01335620 · Phase 4 · registry result, not featured evidence · combination
0%Intervention Arm No.1
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
7.1%Intervention Arm No.2
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
—Hyper-immune Bovine Colostrum
NCT00772590 · Phase 4 · registry result, not featured evidence
—Raltegravir + Hyper-immune Bovine
NCT00772590 · Phase 4 · registry result, not featured evidence · combination
—
NCT00631449 · Phase 4 · registry result, not featured evidence
—1200 mg QD
NCT03029689 · Phase 3 · registry result, not featured evidence · combination
—
NCT02284035 · Phase 3 · registry result, not featured evidence · combination
—1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
1.3%Reformulated Raltegravir
NCT02131233 · Phase 3 · registry result, not featured evidence
Serious AEs
20%e
NCT02607956 · Phase 3 · HIV · phase 3
show 15 more results
14%B/F/TAF
NCT02607930 · Phase 3 · HIV · phase 3
7.5%B/F/TAF to B/F/TAF
NCT02607930 · Phase 3 · HIV · phase 3
—B/F/TAF
NCT03110380 · Phase 3
12.7%Double-Blind Treatment Phase B/F/T
NCT03110380 · Phase 3
9.6%Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3
9.5%Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · combination
5%
NCT04530630 · Phase 4 · registry result, not featured evidence
4%
NCT05405751 · Phase 4 · registry result, not featured evidence
0%
NCT03656783 · Phase 3 · registry result, not featured evidence
—BIC + F/TAF
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
6.2%BIC + F/TAF (Double-Blind Randomiz
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
0%50 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
0%100 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
0%5 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
—400 mg b.i.d.f
NCT00293254 · Phase 3 · combination
show 27 more results
34.8%400 mg b.i.d.
NCT00293254 · Phase 3 · combination
41.8%400 mg b.i.d
NCT00293267 · Phase 3 · combination
—400 mg b.i.d
NCT00293267 · Phase 3 · combination
20.3%400 mg b.i.d.
NCT00369941 · Phase 3
21.1%
NCT01147107 · Phase 4 · registry result, not featured evidence
0%
NCT03374358 · Phase 4 · registry result, not featured evidence
0%
NCT03667547 · Phase 4 · registry result, not featured evidence
0%Arm A Raltegravir
NCT03205566 · Phase 4 · registry result, not featured evidence
0%Arm B Raltegravir Lamivudine
NCT03205566 · Phase 4 · registry result, not featured evidence · combination
0%
NCT02383355 · Phase 4 · registry result, not featured evidence
13.5%
NCT00939874 · Phase 4 · registry result, not featured evidence
3.8%
NCT00843713 · Phase 4 · registry result, not featured evidence
5.6%
NCT01332227 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00870363 · Phase 4 · registry result, not featured evidence · combination
—Switch to Tenofovir/Emtricitabine
NCT01270802 · Phase 4 · registry result, not featured evidence · combination
0%Switch to Tenofovir/Emtricitabine/
NCT01270802 · Phase 4 · registry result, not featured evidence
7.1%
NCT00762892 · Phase 4 · registry result, not featured evidence
0%
NCT01335620 · Phase 4 · registry result, not featured evidence · combination
13.3%Intervention Arm No.1
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
14.3%Intervention Arm No.2
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
0%Hyper-immune Bovine Colostrum
NCT00772590 · Phase 4 · registry result, not featured evidence
5.3%Raltegravir + Hyper-immune Bovine
NCT00772590 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00631449 · Phase 4 · registry result, not featured evidence
0%1200 mg QD
NCT03029689 · Phase 3 · registry result, not featured evidence · combination
6.1%
NCT02284035 · Phase 3 · registry result, not featured evidence · combination
9.6%1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
—Reformulated Raltegravir
NCT02131233 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
e
diarrhoea 20.6%
headache 17.8%
nasopharyngitis 15.9%
NCT02607956 · Phase 3 · HIV · phase 3
show 12 more results
diarrhoea 17.2%
upper respiratory tract infection 14.6%
headache 14%
NCT02607930 · Phase 3 · HIV · phase 3
syphilis 8.7%
covid-19 7.9%
nasopharyngitis 7.1%
NCT02607930 · Phase 3 · HIV · phase 3
nasopharyngitis 15.5%
upper respiratory tract infection 11.6%
diarrhoea 9.2%
NCT03110380 · Phase 3
upper respiratory tract infection 7.2%
arthralgia 3.2%
bronchitis 3.2%
NCT03110380 · Phase 3
upper respiratory tract infection 8.6%
diarrhoea 6%
fatigue 6%
NCT03110380 · Phase 3 · combination
loose stool/ diarrhea 25%
NCT04530630 · Phase 4 · registry result, not featured evidence
shortness of breath 8%
NCT03656783 · Phase 3 · registry result, not featured evidence
diarrhoea 13.8%
upper respiratory tract infection 10.8%
headache 9.2%
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
50 mg
fatigue 25% (placebo 0%)
papule 25% (placebo 0%)
arthropod bite 0% (placebo 0%)
NCT02275065 · Phase 1 · registry result, not featured evidence
100 mg
arthropod bite 25% (placebo 0%)
diarrhoea 25% (placebo 0%)
headache 25% (placebo 25%)
NCT02275065 · Phase 1 · registry result, not featured evidence
25 mg
headache 25% (placebo 25%)
arthropod bite 0% (placebo 0%)
blood creatine phosphokinase increased 0% (placebo 0%)
NCT02275065 · Phase 1 · registry result, not featured evidence
5 mg
blood creatine phosphokinase increased 25% (placebo 0%)
diarrhoea 25% (placebo 0%)
headache 25% (placebo 25%)
NCT02275065 · Phase 1 · registry result, not featured evidence
400 mg b.i.d.f
upper respiratory tract infection 33% (placebo 24.4%)
diarrhoea 32.6% (placebo 29.4%)
fatigue 19.6% (placebo 15.1%)
NCT00293254 · Phase 3 · combination
show 17 more results
400 mg b.i.d
diarrhoea 31.9% (placebo 28.8%)
nasopharyngitis 25% (placebo 17.8%)
bronchitis 18.1% (placebo 13.6%)
NCT00293267 · Phase 3 · combination
400 mg b.i.d.
nasopharyngitis 26.7%
headache 26%
diarrhoea 25.6%
NCT00369941 · Phase 3
alt elevation 55.3%
NCT01147107 · Phase 4 · registry result, not featured evidence
sleeping difficulties 52.6% (placebo 54.2%)
gastrointestinal (diarrhoea, nausea) 47.4% (placebo 29.2%)
headache 47.4% (placebo 33.3%)
NCT03374358 · Phase 4 · registry result, not featured evidence
runny nose 10.5%
cold 5.3%
diarrhoea 5.3%
NCT03205566 · Phase 4 · registry result, not featured evidence
nightmares and vivid dreams 13.2%
diarrhoea 7.9%
headache 7.9%
NCT03205566 · Phase 4 · registry result, not featured evidence · combination
headache 5.3%
insomnia 5.3%
NCT02383355 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 18.9%
diarrhoea 10.8%
abdominal cramps 5.4%
NCT00939874 · Phase 4 · registry result, not featured evidence
hyperbilirubinemia 3.8% (placebo 0%)
NCT00843713 · Phase 4 · registry result, not featured evidence
hyperbilirubinaemia 8.3%
ocular icterus 8.3%
bronchitis 5.6%
NCT01332227 · Phase 4 · registry result, not featured evidence · combination
gastrointestinal intolerance 9.1%
neuropsychiatric side effect 0%
NCT00870363 · Phase 4 · registry result, not featured evidence · combination
neutropenia 6.7%
diastolic hypertension 0%
impaired fasting glucose 0%
NCT01270802 · Phase 4 · registry result, not featured evidence
bronchitis 20%
diarrhea 20%
headache 20%
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
diarrhea 21.4%
upper respiratory infection 21.4%
fatigue 14.3%
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
1200 mg QD
adverse event not related to the treatment 2.6% (placebo 5.6%)
NCT03029689 · Phase 3 · registry result, not featured evidence · combination
insomnia 8.2%
amigdalitis 6.1%
common cold 6.1%
NCT02284035 · Phase 3 · registry result, not featured evidence · combination
1200 mg QD + Truvada
headache 15.8%
nausea 13.6%
diarrhoea 13.4%
NCT02131233 · Phase 3 · registry result, not featured evidence · combination

Notes

  1. aTrial phases differ: Phase 2 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dTrial phases differ: Phase 4 versus Phase 3.
  5. ePopulation comparability has not been reviewed for 13 of these studies.
  6. fPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Bictegravir

HIV-1 RNA Less Than 20 82.2% (n=320) vs 87.1% (n=325) DTG + F/TAF @ 48wk
responder rate · % of participants
NCT02607956 · Phase 3 · HIV · phase 3
show 5 more results
77.5% (n=320) vs 80.3% (n=325) DTG + F/TAF @ 96wk
NCT02607956 · Phase 3 · HIV · phase 3
77.5% (n=320) vs 79.1% (n=325) DTG + F/TAF @ 144wk
NCT02607956 · Phase 3 · HIV · phase 3
87.6% (n=314) vs 87.3% (n=315) ABC/DTG/3TC @ 48wk
NCT02607930 · Phase 3 · HIV · phase 3
83.4% (n=314) vs 84.8% (n=315) ABC/DTG/3TC @ 96wk
NCT02607930 · Phase 3 · HIV · phase 3
78% (n=314) vs 82.2% (n=315) ABC/DTG/3TC @ 144wk
NCT02607930 · Phase 3 · HIV · phase 3
HIV-1 RNA -1.37 vs -0.01 placebo log @ 1.57wk50 mg
absolute change · log
NCT02275065 · Phase 1 · registry result, not featured evidence
show 12 more results
-1.61 vs -0.01 placebo log @ 1.57wk100 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
-1.33 vs -0.01 placebo log @ 1.57wk25 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
-0.92 vs -0.01 placebo log @ 1.57wk5 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
-3.07 vs -3.12 DTG + F/TAF log @ 48wk
NCT02607956 · Phase 3 · HIV · phase 3
-3.08 vs -3.1 DTG + F/TAF log @ 96wk
NCT02607956 · Phase 3 · HIV · phase 3
-3.06 vs -3.11 DTG + F/TAF log @ 144wk
NCT02607956 · Phase 3 · HIV · phase 3
-3.11 vs -3.07 ABC/DTG/3TC log @ 48wk
NCT02607930 · Phase 3 · HIV · phase 3
-3.09 vs -3.1 ABC/DTG/3TC log @ 96wk
NCT02607930 · Phase 3 · HIV · phase 3
-3.11 vs -3.1 ABC/DTG/3TC log @ 144wk
NCT02607930 · Phase 3 · HIV · phase 3
-3.03 vs -3.15 DTG + F/TAF log @ 12wk
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
-3.09 vs -3.12 DTG + F/TAF log @ 24wk
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
-3.09 vs -3.11 DTG + F/TAF log @ 48wk
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
HIV-1 RNA Less Than 50 Copies 25% (n=4) vs 0% (n=4) placebo @ 2.43wk50 mg
responder rate · % of participants
NCT02275065 · Phase 1 · registry result, not featured evidence
show 10 more results
50% (n=4) vs 0% (n=4) placebo @ 2.43wk100 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
0% (n=4) vs 0% (n=4) placebo @ 2.43wk25 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
0% (n=3) vs 0% (n=4) placebo @ 2.43wk5 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
92.4% (n=314) vs 93% (n=315) ABC/DTG/3TC @ 48wk
NCT02607930 · Phase 3 · HIV · phase 3
87.9% (n=314) vs 89.8% (n=315) ABC/DTG/3TC @ 96wk
NCT02607930 · Phase 3 · HIV · phase 3
81.5% (n=314) vs 84.1% (n=315) ABC/DTG/3TC @ 144wk
NCT02607930 · Phase 3 · HIV · phase 3
93.3% (n=284) vs 91.1% (n=281) DTG + F/TAF @ 48wk
NCT03110380 · Phase 3
96.9% (n=65) vs 93.9% (n=33) DTG + F/TAF @ 24wk
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
93.8% (n=65) vs 93.9% (n=33) DTG + F/TAF @ 12wk
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
96.9% (n=65) vs 90.9% (n=33) DTG + F/TAF @ 48wk
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
Hip BMD -0.802% (n=278) vs -1.148% (n=281) ABC/DTG/3TC @ 48wk
percent change · % of baseline
NCT02607930 · Phase 3 · HIV · phase 3
show 2 more results
-1.128% (n=250) vs -1.262% (n=257) ABC/DTG/3TC @ 96wk
NCT02607930 · Phase 3 · HIV · phase 3
-1.02% (n=236) vs -1.291% (n=240) ABC/DTG/3TC @ 144wk
NCT02607930 · Phase 3 · HIV · phase 3
Spine BMD -0.772% (n=284) vs -0.552% (n=285) ABC/DTG/3TC @ 48wk
percent change · % of baseline
NCT02607930 · Phase 3 · HIV · phase 3
show 2 more results
-0.705% (n=256) vs -0.219% (n=258) ABC/DTG/3TC @ 96wk
NCT02607930 · Phase 3 · HIV · phase 3
-0.371% (n=243) vs 0.035% (n=244) ABC/DTG/3TC @ 144wk
NCT02607930 · Phase 3 · HIV · phase 3
HIV-1 RNA Ge50 Copies 0.4% (n=284) vs 1.1% (n=281) DTG + F/TAF @ 48wk
responder rate · % of participants
NCT03110380 · Phase 3
Virologic Suppression 100% (n=19) @ 48wk
event count · % of participants
No placebo or comparator arm
NCT04530630 · Phase 4 · registry result, not featured evidence · converted to % from 19 Participants as posted
CD4 25.667% (n=19) @ 4wk
percent change · % of baseline
No placebo or comparator arm
NCT04530630 · Phase 4 · registry result, not featured evidence
show 4 more results
25.7368% (n=19) @ 12wk
NCT04530630 · Phase 4 · registry result, not featured evidence
27.0526% (n=19) @ 24wk
NCT04530630 · Phase 4 · registry result, not featured evidence
28.1111% (n=19) @ 36wk
NCT04530630 · Phase 4 · registry result, not featured evidence
26.1579% (n=19) @ 48wk
NCT04530630 · Phase 4 · registry result, not featured evidence
Allograft Rejection 0% (n=19) @ 48wk
event count · % of participants
No placebo or comparator arm
NCT04530630 · Phase 4 · registry result, not featured evidence · converted to % from 0 Participants as posted

Raltegravir

HIV RNA Less Than 400 Copies 77.3% (n=229) vs 42.9% (n=119) placebo @ 16wk400 mg b.i.d.
responder rate · % of participants
NCT00293254 · Phase 3 · combination
show 5 more results
71.1% (n=228) vs 37.8% (n=119) placebo @ 48wk400 mg b.i.d.
NCT00293254 · Phase 3 · combination
50.2% (n=229) vs 21% (n=119) placebo @ 156wk400 mg b.i.d.
NCT00293254 · Phase 3 · combination
77.7% (n=229) vs 41% (n=117) placebo @ 16wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
73.6% (n=231) vs 36.4% (n=118) placebo @ 48wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
57.3% (n=232) vs 25.6% (n=117) placebo @ 156wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
HIV RNA Less Than 400 Copies 45.7% (n=230) vs 13.4% (n=119) placebo @ 240wk400 mg b.i.d.
responder rate · % of participants
Extension (open-label)
NCT00293254 · Phase 3 · combination
show 1 more result
45.3% (n=232) vs 20.3% (n=118) placebo @ 240wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
HIV RNA Less Than 50 Copies 41.3% (n=230) vs 13.4% (n=119) placebo @ 240wk400 mg b.i.d.
responder rate · % of participants
Extension (open-label)
NCT00293254 · Phase 3 · combination
show 1 more result
42.2% (n=232) vs 18.6% (n=118) placebo @ 240wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
Without Loss of Virologic 44.3% (n=230) vs 17.6% (n=119) placebo @ 156wk400 mg b.i.d.
responder rate · % of participants
NCT00293254 · Phase 3 · combination
HIV-1 RNA -1.92 vs -1.06 placebo copies/mL @ 16wk400 mg b.i.d.
absolute change · copies/mL
NCT00293254 · Phase 3 · combination
show 6 more results
-1.75 vs -0.87 placebo copies/mL @ 48wk400 mg b.i.d.
NCT00293254 · Phase 3 · combination
-1.37 vs -0.52 placebo copies/mL @ 156wk400 mg b.i.d.
NCT00293254 · Phase 3 · combination
-1.85 vs -0.78 placebo copies/mL @ 16wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
-1.67 vs -0.68 placebo copies/mL @ 48wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
-1.44 vs -0.51 placebo copies/mL @ 156wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
-3.05 vs -3.29 Atazanavir copies/mL @ 48wk
NCT00762892 · Phase 4 · registry result, not featured evidence
HIV-1 RNA -1.31 vs -0.41 placebo copies/mL @ 240wk400 mg b.i.d.
absolute change · copies/mL
Extension (open-label)
NCT00293254 · Phase 3 · combination
show 1 more result
-1.24 vs -0.45 placebo copies/mL @ 240wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
CD4+ 172.1 vs 54.1 placebo cells/uL @ 240wk400 mg b.i.d.
absolute change · cells/uL
Extension (open-label)
NCT00293254 · Phase 3 · combination
show 1 more result
193.6 vs 68.2 placebo cells/uL @ 240wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
HIV-1 RNA Less Than 400 Copies Per 86.1% (n=280) vs 81.9% (n=281) Efavirenz @ 48wk400 mg b.i.d.
event count · % of participants
NCT00369941 · Phase 3 · converted to % from 241 Participants as posted
show 7 more results
90% (n=280) vs 85.8% (n=281) Efavirenz @ 48wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 252 Participants as posted
81.1% (n=281) vs 78.7% (n=282) Efavirenz @ 96wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 228 Participants as posted
85.4% (n=281) vs 81.2% (n=282) Efavirenz @ 96wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 240 Participants as posted
75.4% (n=281) vs 68.1% (n=282) Efavirenz @ 156wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 212 Participants as posted
79.7% (n=281) vs 72% (n=282) Efavirenz @ 156wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 224 Participants as posted
71% (n=279) vs 61.3% (n=279) Efavirenz @ 240wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 198 Participants as posted
73.8% (n=279) vs 64.9% (n=279) Efavirenz @ 240wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 206 Participants as posted
Hepatic Fat Fraction 0.6 vs 0.3 placebo fraction @ 24wk
absolute change · fraction
NCT03374358 · Phase 4 · registry result, not featured evidence
Weight 2 vs 0.9 placebo kg @ 24wk
absolute change · kg
Change in body weight (24 weeks - baseline)
NCT03374358 · Phase 4 · registry result, not featured evidence
Body Fat Mass 1.5 vs -0.3 placebo kg @ 24wk
absolute change · kg
Change in body fat (24 weeks - baseline)
NCT03374358 · Phase 4 · registry result, not featured evidence
Liver Stiffness Fibroscan Change kPa -0.2 vs -0.5 placebo kPa @ 24wk
absolute change · kPa
NCT03374358 · Phase 4 · registry result, not featured evidence

+ 18 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bictegravir's landscape · Raltegravir's landscape